Moberg Pharma AB (OSTO:MOB) FCF Margin % : -2,635.61% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Moberg Pharma AB's Free Cash Flow for the three months ended in Mar. 2024 was kr-21.61 Mil. Moberg Pharma AB's Revenue for the three months ended in Mar. 2024 was kr0.82 Mil. Therefore, Moberg Pharma AB's FCF Margin % for the quarter that ended in Mar. 2024 was -2,635.61%.

As of today, Moberg Pharma AB's current FCF Yield % is -20.68%.

The historical rank and industry rank for Moberg Pharma AB's FCF Margin % or its related term are showing as below:

OSTO:MOB' s FCF Margin % Range Over the Past 10 Years
Min: -41021.26 Med: -21.38 Max: 7.78
Current: -16860.61

During the past 13 years, the highest FCF Margin % of Moberg Pharma AB was 7.78%. The lowest was -41021.26%. And the median was -21.38%.

OSTO:MOB's FCF Margin % is ranked worse than
99.42% of 1029 companies
in the Drug Manufacturers industry
Industry Median: 0.05 vs OSTO:MOB: -16860.61

Moberg Pharma AB FCF Margin % Historical Data

The historical data trend for Moberg Pharma AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB FCF Margin % Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-214.14

-41,021.26

Moberg Pharma AB Quarterly Data
	Mar19	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-2,635.61

Competitive Comparison of Moberg Pharma AB's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's FCF Margin % falls into.

Moberg Pharma AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Moberg Pharma AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-157.321	/	0
	=	%

Moberg Pharma AB's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-21.612	/	0.82
	=	-2,635.61 %

Moberg Pharma AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB (OSTO:MOB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.